Abstract Purpose: Phase I-II studies indicate that imatinib is active in glioblastoma multiforme.
Glioblastoma multiforme is the most common central nervous system tumor in adults and is highly malignant, with a median survival of 16 months from diagnosis. Usually, treatment includes surgery, postoperative radiotherapy, and chemotherapy with temozolomide and/or alkylating agents.
Several growth factors drive and sustain gliomagenesis, among them platelet-derived growth factor (PDGF) and its receptor, PDGFR. Different isoforms of PDGF are expressed in variable amounts, as is the case for PDGFR (1, 2) .
In high-grade gliomas, epidermal growth factor (EGF), its receptor (EGFR), and transforming growth factor a (TGFa) are overexpressed, leading to autocrine and paracrine stimulatory loops (3) .
Imatinib blocks the ATP binding site of the tyrosine kinase proteins BCR, ABL, KIT, and PDGFR, thus inhibiting their activation and the transduction of downstream signals. Imatinib has clinical activity in various diseases (4) (5) (6) , and KIT has been reported to be activated in glioblastoma cells and glioblastoma endothelial cells (7) . In fact, the KIT downstream signaling effectors, m-TOR and AKT, have also been found to be overexpressed in glioblastoma multiforme (7) . Imatinib activity has been shown in glioblastoma multiforme cell lines (8) and mouse models (9) . Phase I and II trials have only yielded modest results, but this could be due to the fact that a targeted agent was used in an unselected population, i.e., in a nontargeted fashion (10, 11) . A phase II study of imatinib in combination with hydroxyurea generated promising results, although the treatment outcome cannot be attributed solely to imatinib (12) .
Although the biochemical effects of imatinib have been well elucidated in gastrointestinal stromal tumors and chronic myelogenous leukemia, the molecular effects of imatinib treatment on glioblastoma multiforme are poorly understood.
This study was designed to investigate the clinical and biological effects of imatinib therapy in glioblastoma multiforme and to verify the inhibition of imatinib targets and their downstream pathways.
We measured the concentration of imatinib in glioblastoma multiforme tissue using mass spectrometry-based proteomic technology (13) , and then evaluated the effect of the drug on proliferation using Ki67 as a marker. Biochemical response, as manifested by changes in the differential activation status pretherapy and posttherapy of several signaling molecules, was also evaluated by Western blotting in an effort to determine which signaling pathways are dysregulated by imatinib in the tumor.
Finally, pharmacokinetic studies were done and serum levels of imatinib (and its metabolite) were correlated with the tissue levels. Those parameters were then associated with microvessel density (MVD) in pretreatment and posttreatment specimens.
Patients and Methods
The protocol was approved by the Institute and Ethics committees of both hospitals involved in the study and by the Greek National Organization of Medicines, Division of Pharmaceutical studies and research (Study Identification number: CST1571BGR03). The participants gave informed consent, and the study was conducted under International Conference on Harmonisation guidelines for Good Clinical Practice and the declaration of Helsinki. Inclusion criteria included age >18 y, measurable disease by magnetic resonance imaging, adequate endorgan function, and life expectancy of ≥3 mo.
Patients with newly diagnosed brain tumors that were radiogically consistent with glioblastoma multiforme were evaluated clinically and, if eligible, were accrued to the protocol. The tumor was biopsied under computerized tomography (CT) guidance. Once glioblastoma multiforme diagnosis was confirmed, the patient was started on imatinib 400 mg orally, twice daily for 7 d (14 doses). Corticosteroid dose had to remain stable throughout the 7 d, and the only antiepileptic agent allowed was valproic acid because it does not induce the CYP3A4 major p450 human enzymes that catalyze imatinib biotransformation.
Six to twenty-four hours after the last dose of imatinib the patients underwent definitive (cytoreductive) surgery or, if not resectable, a second CT-guided biopsy. For two patients, however, surgery was delayed. For the first patient, the delay was due to intensive care unit unavailability, whereas the second patient developed pulmonary complications that required hospitalization and mechanical support.
Each time six specimens were obtained. Two or more of them were snap-frozen, whereas the rest were fixed in paraffin.
Immunohistochemistry. Tumor samples from 20 patients were tested for proliferative activity and MVD by immunohistochemistry. The material consisted of formalin-fixed paraffin-embedded tissue blocks of pretreatment surgical biopsies as well as after-treatment surgical biopsies. However, three of the pretreatment samples and two of the posttreatment samples, five tissue samples in total, were nonevaluable due to extensive necrosis. The pretreatment MVD was not evaluated in an additional case, because after testing for Ki67 the remaining material was insufficient for further analysis.
Immunohistochemical assays for CD34 (clone QBEnd/10, Novocastra) and Ki-67 (clone MIB-1, Dako) were done.
Scoring system for interpretation of immunohistochemical markers Ki67 (MIB-1). Ki67 immunostaining was scored as previously described (14) . Briefly, 500 neoplastic cells were counted in 10 representative fields (hot points) using a high-power (×40) objective with a grid screen. All stained cells were recorded as positive irrespective of the staining intensity. The percentage of positively stained cells, termed the proliferation index, was calculated and recorded.
CD34. Intratumoral MVD was assessed as previous described, with slight modifications (15) . Specifically, nonnecrotic tumor areas of highest neovascularization (hot spots) were found by scanning the tumor sections at low-power magnification (×4 or ×10 total magnification). After the identification of highest neovascularization areas, microvessel counting was carried out on three high-power fields and expressed as the mean MVD. Any single endothelial cell or cluster of endothelial cells was counted as a single microvessel. Muscle vessels were not counted. The mean value for the three fields with MVD was recorded as the MVD for each tumor and expressed as the number of vessels of three counts.
Pharmacokinetics. Blood specimens for pharmacokinetics were obtained on the final day of treatment. Specifically, trough levels were drawn 11 h after the 13th or 14th dose of imatinib. After centrifugation at 1,500 g plasma was stored at -20°C.
Imatinib mesylate and its major active metabolite N-desmethyl CGP4588 were measured at the reference laboratory of Novartis Pharma in Paris, France. The previously established technique using liquid chromatography and mass spectroscopy for imatinib and its metabolite was used (16, 17) .
Quantitation of imatinib in tumor samples. Quantitation of imatinib in tissue was done using liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) on individual patients' postsurgery samples. Additionally, four presurgery samples were pooled for use as blanks and to make representative calibration samples. Tissue sample homogenates were made by combining tissue and PBS in a ratio of 1:4 (mg/μL). Prior to protein precipitation, particulates are removed from samples by centrifugation (3,000 g, 5 min). All samples were analyzed in triplicate, including blank samples and quality control samples containing 1,000 μg/mL imatinib
Translational Relevance
The understanding of the molecular and biochemical effects of imatinib in glioblastoma multiforme may contribute to a better tailoring of treatment with imatinib in this or other tumors, both by the identification of patient subgroups most likely to benefit from such treatment and by the understanding of all related pathways. Furthermore, this form of drug-efficacy testing (neoadjuvant therapy with pretreatment and posttreatment biopsies) could serve as a model for future testing of other targeted therapies in other tumors.
and deuterium 8-labeled imatinib (d8-imatinib). For analysis of the drug the Thermo TSQ Quantum, Surveyor HPLC system was used and a HPLC Column: XTerra RP C18, 100 mm × 2.1 mm (Waters) was applied.
The average imatinib concentration was computed using the coefficients from the linear regression, and the errors (SD) were reported. Standard compounds, imatinib and d8-imatinib, were provided by Novartis. The methodology employed for this study was similar to that described by Titier et al. (16) . The limit of detection for imatinib was <1 ng/mL of tissue homogenate, and the limit of quantitation was 10 ng/mL. It was found that these results compare favorably with imatinib assays previously reported for plasma (13, 16 ). For quality control purposes, a sample containing 1,000 ng/mL of both imatinib and d8-imatinib and a blank (no imatinib) sample were measured at the beginning of the experiment, end of the experiment, and between each replicate measurement of the patient sample set (n = 4). Blank injections (data not shown) confirmed that no detectable carryover of imatinib was observed.
Western blotting and reagents. Cell lysate preparations from frozen tumors, protein quantization, electrophoresis, and immunoblotting were carried out as described previously (18, 19) . Protein expression levels in glioblastoma biopsies were compared pretreatment and posttreatment with imatinib. Chemiluminescence signals were captured and quantified using a FUJI LAS1000plus system with Science Lab 2003 ImageGauge V2.2 software (Fuji film Medical Systems). Polyclonal rabbit antibodies to phospho-KIT Y703, mitogen-activated protein kinase (MAPK) p42/44, and phospho-EGFR were from Invitrogen Laboratories. Polyclonal rabbit antibodies to phospho-AKT S473, total AKT, and phospho-MAPK p42/44 T202/Y204 were from Cell Signaling; phospho-PDGFR, total PDGFRα and β, KIT, and EGFR were from Santa Cruz; phosphoinositide 3-kinase (PI3-K) p85 was from Millipore. Mouse monoclonal anti-p27 (clone 57) was from BD Transduction Laboratories.
Results
A total of 20 patients, 14 male and six female, were assessed. Median tumor size was 51 mm in the greatest diameter. Two patients had a performance status (PS) on the Eastern Cooperative Oncology Group (ECOG) scale of 0, nine had a PS of 1, and nine patients had a PS of 2. Histology showed mixed glioblastoma multiforme and astrocytoma in 3 patients and pure glioblastoma multiforme in 17. Clinical (radiologic) response was assessed by magnetic resonance imaging on the 7th day of therapy. In 18 patients the tumor remained stable, whereas in 1 patient disease progressed and 1 patient was nonevaluable because he did not undergo posttreatment magnetic resonance imaging.
Median survival was 6.2 months (range, 1.1-17.9 months). Twelve patients underwent a partial or total resection after treatment and eight underwent a second biopsy only. Only 13 of the 20 patients received standard adjuvant temozolomide chemotherapy and radiotherapy. The reasons for not having standard treatment were (a) poor PS and early death in five patients, and (b) refusal/loss to follow-up in two. Three patients had alkylator-based therapy after relapse and one patient survived an exceptionally long period of 18 months.
Grade III toxicity was respiratory in two, urinary tract infection in one, fatigue/anemia in two, central nervous system in three (one seizure, one dysarthria, and one epidural hematoma), and poorly controlled glucose in one patient with diabetes mellitus.
Pharmacokinetics. The median trough level of imatinib (STI 571) was 1,510 ng/mL (range, 655-2,630 ng/mL); the median trough level of CGP 74588 was 421 ng/mL (range, 292-557 ng/mL).
Availability of good-quality tissue specimens for testing was limited by the small size of the biopsy specimens, which additionally, as expected in glioblastoma multiforme, had areas of necrosis in them. However, there were 14 good-quality, matched pretreatment and posttreatment specimen pairs for biochemical analysis, and in 15 cases there was posttreatment tissue available for imatinib tissue level measurement.
Quantitation of imatinib in tissue. The imatinib analysis in the tissue confirmed the feasibility of applying LC/MS/MS to evaluate the drug level. Results are shown in Fig. 1 . It was found that the measurement of imatinib was linear with respect to concentration across a minimum of three orders of magnitude. (r 2 = 0.9992). The limit of detection for imatinib was <1 ng/mL of tissue homogenate, and the limit of quantitation was 10 ng/mL. It was found that these results were in agreement with previously reported levels of imatinib in plasma. For quality control purposes, a sample containing 1,000 ng/mL of both imatinib and d8-imatinib and a blank (no imatinib) sample were measured at the beginning of the experiment, end of the experiment, and between each replicate measurement of the patient samples (n = 4). The blank results (data not shown) confirmed that no detectable carryover of imatinib was observed. Additionally, replicate measurement of the standard showed that the ratio of [imatinib]/[d8-imatinib] was not substantially changed (CV = 1.94%) after measurement of >75 samples. The amount of imatinib in each of the treated patients was determined using LC/MS/MS, and imatinib levels were found to range between 1,180 and 3,323 ng/g of tumor tissue, with a median value of 1,530 ng/g.
There was no correlation between trough plasma levels of imatinib and average tissue imatinib levels (Spearman's r = 0.07, P = 0.865).
Furthermore, no correlation was identified between CGP74588 levels and average imatinib tissue concentration (Spearman's r = 0.05, P = 0.898).
Three of the twenty patients showed low average tissue concentration relative to their CGP74588 concentration. None of these patients showed a biochemical response, whereas their MVD remained relatively low posttreatment.
These three patients survived for 2.2, 2.3, and 3.8 months.
Immunohistochemistry. Ki67 pretreatment and post treatment was assessed as a marker proliferation. No identifiable change in Ki67 expression was detected. Furthermore, CD34 was tested as a marker of tumor vascularity (MVD), in order to correlate it with tissue levels of imatinib. There was a slight identifiable upward trend in MVD posttherapy without any significant correlation to serum or tissue levels of imatinib.
No significant correlation between the pretreatment MVD and the average imatinib tissue levels was detected (Spearman's r = -0.15, P = 0.628).
Biochemical response to imatinib. Biochemical responses to imatinib were characterized by examining oncogenic AKT and MAPK signaling pathways. Of the 20 patients studied, 16 showed variable AKT and MAPK phosphorylation, ranging from marginally detectable to high. Of 14 patients with matched pre-and post-imatinib treatment biopsies, 3 were not evaluable because of unequal cell protein levels in pretreatment and posttreatment samples (Table 1 ). Among the 11 analyzable patients, expression of the p27 antiproliferation checkpoint protein increased after imatinib treatment in two patients (Fig. 2) . Immunoblotting quantitations showed that AKT phosphorylation (assessed as ratio of phosphorylated to total AKT) decreased 7.6-fold in the post-imatinib biopsy in patient 001/1, whereas MAPK per molecule phosphorylation decreased 1.1-fold in patient 009/2 (Fig. 2) . Patient 003/2 had high-level PDGFRB activation, which was not inhibited after imatinib treatment (Fig. 3) , nor was AKT or MAPK inhibited by imatinib treatment in this individual. We could not show a PDGFRB genomic mutation in exons 11, 13, and 17 (data not shown) in this tumor. The tumors from patients 003/1 and 007/2 showed high-level EGFR activation, and denaturing high-performance liquid chromatography mutational analyses and sequencing studies revealed homozygous EGFR exon 3 (R108K) and exon 15 (G598V) missense mutations in these tumors, respectively.
Discussion
The role of imatinib in glioblastoma multiforme has been studied in combination with radiotherapy and hydroxyurea, and as a single agent, in several trials designed to examine clinical efficacy in the general glioblastoma multiforme population 
without selecting for a particular target (11, 12) . The lack of clinical efficacy observed in those studies could have been explained in several different ways. It is conceivable that imatinib did not reach therapeutic levels in the plasma or tumor because of the concurrent use of enzyme-inducing antiepileptic drugs (EIAED). Alternatively, a high percentage of the glioblastoma multiforme patients included in those studies might not have expressed the relevant kinase targets or in those patients' tumors the target might not have been constitutively activated. The present study was designed to address these questions and to examine the effect of imatinib in glioblastoma multiforme in a systematic fashion. First, by standardizing the antiepileptic regimen and using the non-EIAED valproic acid, steady plasma levels of imatinib were ensured and when measured, the plasma levels were comparable with those published in other tumors (20) . In fact, in two important subsequent studies with the hydroxyurea/imatinib combination and the irinotecan/bevacizumab combination, the effect and toxicity of the regimens depended on the use of EIAED (21, 22) .
Furthermore, because the ability of drugs to reach brain tumors is always questioned, imatinib was measured in tissue using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. Measuring the tissue concentration of a drug does not imply measuring exclusively intracellular levels. However, the evaluation of imatinib in tissue coupled with the posttreatment molecular and biochemical changes we have observed may constitute indirect evidence that the levels measured are at least partially intracellular. We examined pretreatment tumor vascularity in order to explain the difference in the range of average tissue and plasma levels but no relationship was found. Furthermore, we attempted to detect an effect of imatinib on proliferation, as reflected by changes in Ki67 expresssion immunohistochemically. No such effect was seen. Biochemical changes were detected, however, in some posttreatment specimens, compared with those obtained before treatment. Specifically, decreased phosphorylation of AKT and MAPK or increased expression of the p27 antiproliferation checkpoint protein was shown in 4 of 11 patients, suggestive of biochemical responses in these tumors. Notably, prior studies have indicated that the effect of imatinib on PDGFR in glioblastoma multiforme may be mediated via the AKT pathway (23) . However, in the only glioblastoma multiforme showing high-level PDGFRB phosphorylation (patient 003/2), imatinib treatment had no apparent effect on PDGFRB activation, nor on activation of downstream signaling intermediates AKT and MAPK, and denaturing high-performance liquid chromatography and sequencing analyses (data not shown) did not reveal a definable PDGFRB genomic mutation. This observation suggests that activation of wild-type PDGFRB may not be adequately suppressed by imatinib treatment in glioblastoma multiforme, but it is also possible that this glioblastoma multiforme contained a novel PDGFRB mutation, which was resistant to imatinib therapy. Other investigators have detected effects of imatinib on MAPK in glioblastoma multiforme cell lines (24, 25) , and it is widely believed that the potential target of imatinib in glioblastoma multiforme is PDGFR. Although several studies have examined the biochemical effect of imatinib on glioblastoma multiforme cell lines and some of them describe an effect on PDGFR (26) , it is also well documented that certain gain-of-function mutations in PDGFR, BCR-ABL, and KIT are imatinib resistant (27, 28) .
The oncogenic role of EGFR in glioblastoma multiforme in previous studies seems to be due to amplification and/or mutations in the EGFR gene (29, 30) . Not surprisingly, we found two patients with high-level EGFR activation in this study, and each of those tumors had a known gain-of-function EGFR mutation (R108K and G598V), which was homozygous at the genomic level. In one report, 15% to 20% of glioblastoma patients showed clinical response to small-molecule EGFR kinase inhibitors (31) . The persistence of high-level EGFR activation in posttreatment samples from these two patients is in keeping with the oncogenic EGFR mechanism, which may afford the cells a selective advantage to thrive during imatinib therapy. It is well known that glioblastoma multiforme cells are very heterogeneous at the molecular level, with each abnormality appearing in low frequencies. Those abnormalities differentially activate and silence relevant signaling pathways. Thus, it may be that a particular target (namely PDGFRB, EGFR, AKT, or MAPK) may be more important in some patients than in others (32, 33) . Furthermore, multiple signaling pathways may be activated concurrently and this redundancy may contribute to the resistance to single agents. For this reason, it is also possible that the biochemical evidence for AKT and MAPK inhibition, seen in two patients herein, represented biologic heterogeneity in the specimens analyzed before and after imatinib, rather than being a direct consequence of imatinib-mediated kinase inhibition. In a recent publication (34) the combination of erlotinib with imatinib and another receptor tyrosine kinase inhibitor, SU11274, on glioblastoma multiforme xenografts and cell lines enabled more effective target inhibition than the use of any of these agents alone.
There are several limitations in the present study. The short duration of treatment and the small number of patients precluded us from detecting a clinical (radiologic) effect that could in turn be correlated with the biochemical and protein effect for a more firm result, but because temozolomide and radiotherapy constitute standard therapy, it would have been unethical to delay this treatment.
Another consideration was the inherent extensive necrosis in brain tumors. Stereotactic biopsy specimens are small and the presence of necrosis results in even less tissue available for analysis. Additionally, necrosis hinders the assessment of response on magnetic resonance imaging, thus obstructing the correlation of clinical response with biochemical and protein changes. In fact, we attempted to evaluate the effect of imatinib on a proteomic level as well. Unfortunately, although peptide changes in pretreatment and posttreatment specimens were observed, the identification of the peptides was hindered by the lack of adequate tissue specimens, thus limiting the value of these observations. We feel it would be useful to pursue this type of proteomic investigation in the future.
In this study we observed a lower-than-expected overall survival, although two thirds of our patients did have standard temozolomide and radiotherapy after protocol completion, i.e., with a 2-to 4-week delay. One explanation for the short overall survival is that the surgeons opted to enroll patients with larger and thus particularly aggressive tumors, as those were less likely Fig. 2 . Imatinib effects on AKT and MAPK activation, and p27 expression. PI3-K serves as a loading control, and quantitation of activated and total AKT and MAPK (numbers) was done in relationship to an identical internal standard on each blot. Imatinib treatment was associated with reduction in per molecule AKT and MAPK phosphorylation in GBM 001/1 and 009/2, respectively. Imatinib treatment was associated with increased p27 expression in GBM 007/2, 013/2, 003/1, and 017/2. to benefit from the standard approach. This seems consistent with the fact that almost half of the patients had a PS of 2 and almost half of the patients were not deemed eligible for definitive surgery on day 8, and thus proceeded with a second biopsy only. Furthermore, a full third of the patients did not receive standard therapy after protocol completion. In fact, the published literature supports the fact that older patients with poor PS that have not been debulked carry a worse prognosis (35) .
However, this study is unique in its kind in glioblastoma multiforme because it examines the effect of a targeted agent in this tumor in a systematic way. In fact, in a recently published phase II study of imatinib in patients with recurrent gliomas, the authors point out the need for this type of investigation of drug penetration and target inhibition (36) .
Overall this study provides proof of principle that rational trial design is feasible in gliomas and that the application of advanced technology can generate important data for a better understanding of the mechanism of action of targeted agents. Although there is extensive basic research in this area, we found that there is a paucity of translational studies. The importance of different mutations in glioma should be identified so that targeted agents are used accordingly. Although this study confirms the presence of imatinib in glioblastoma multiforme tissue and shows its molecular effects in a subset of patients, our results do not suggest a benefit from the use of the drug as a single agent in unselected glioblastoma multiforme patient populations. Instead, our results would suggest that the role of imatinib in glioblastoma multiforme needs to be elucidated further using a longer schedule, correlative science studies, and functional imaging.
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